The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multicenter prospective phase II trial of neoadjuvant (neo) dose dense gemcitabine and cisplatin (DD-GC) in patients (pts) with muscle-invasive bladder cancer (MIBC).
 
Arjun Vasant Balar
No Relationships to Disclose
 
Gopa Iyer
No Relationships to Disclose
 
Matthew I. Milowsky
Research Funding - Astellas Pharma (Inst); BIND Therapeutics (Inst); Cerulean Pharma (Inst); Dendreon (Inst); Exelixis (Inst); Johnson & Johnson (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst)
 
William C. Huang
No Relationships to Disclose
 
Michael Woods
No Relationships to Disclose
 
S. Machele Donat
No Relationships to Disclose
 
Harry W. Herr
No Relationships to Disclose
 
Guido Dalbagni
No Relationships to Disclose
 
Bernard H. Bochner
No Relationships to Disclose
 
Irina Ostrovnaya
No Relationships to Disclose
 
Hikmat Al-Ahmadie
No Relationships to Disclose
 
Tracy Lynn Rose
No Relationships to Disclose
 
Jamie Cathleen Riches
No Relationships to Disclose
 
Brooke Elizabeth Kania
No Relationships to Disclose
 
Ashley Marie Regazzi
No Relationships to Disclose
 
Asia S. McCoy
No Relationships to Disclose
 
Daniela Delbeau
No Relationships to Disclose
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina; Merck
Honoraria - UpToDate
Consulting or Advisory Role - Agensys; Boehringer Ingelheim; Bristol-Myers Squibb; Dendreon; Janssen Oncology; Johnson & Johnson; Lilly; Merck; Oncogenex; Onyx; Roche/Genentech
Research Funding - Agensys; Genentech; Mirati Therapeutics; Oncogenex
Patents, Royalties, Other Intellectual Property - ERCC2 predicting cisplatin sensitivity
Travel, Accommodations, Expenses - Genentech/Roche
 
Dean F. Bajorin
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Genentech; Merck; Novartis; Roche; Roche/Genentech
Research Funding - Amgen (Inst); dendreon (Inst); Genentech/Roche (Inst); Merck; Novartis (Inst)
Travel, Accommodations, Expenses - Merck; Roche/Genentech